Deadline: 31-Dec-22
AiCuris is accepting applications for AiCubator: A New Way of Collaboration in Anti- infective Area.
AiCuris strongly believes that there is a need to encourage the development of more early projects based on new scientific principles to fill pipeline gaps, tackle AMR and prevent future pandemics.
Benefits
- To promote early ideas that might lead to the next resistant breaking antibiotic or anti-infective, AiCuris has launched the AiCubator, an innovative corporate incubator that provides first-hand and long-term support (up to 3 years) for such research projects from a leader in anti-infective drug development.
- Scientific support.
- Business Expertise.
- Financing Advisory.
Eligible Projects
- Drug discovery project in the following indications:
- Targeted antiviral therapy, especially for:
- HBV cure
- HIV cure
- BK Virus
- Epstein-Barr virus
- Adenovirus
- Pan-Herpesvirus
- Norovirus
- Pandemic preparedness solutions (RSV, pan-respiratory viruses)
- Antibacterial (non-small molecule) therapy for:
- Bloodstream infections
- Diabetic foot infections
- Antimicrobial resistance
- Osteomyelitis
- Novel platform approach in infectious diseases.
- Targeted antiviral therapy, especially for:
Criteria
- Project Minimal Criteria
- Target identified
- Preliminary efficacy data
- Competitive advantage to existing standard of care
- Applicant
- All applications from companies and scientific groups are welcomed
- Start-up company
- Scientific group within a research university/institute
- Application for the AiCubator
- You are an academic group or a recently formed biotech start-up with antiviral or antibacterial projects?
- You have identified a new breakthrough mechanism of action with supporting data?
- You want this invention to become a therapy for patients?
- You are looking for first-hand support and guidance on your way from a partner with proven experience?
For more information, visit https://www.aicuris.com/57/AiCubator.htm